Design of N-acylprolyltyrosine 'tripeptoid' analogues of neurotensin as potential atypical antipsychotic agents

Journal of Medicinal Chemistry

Volumn 41, Issue 3, 1998, Pages 284-290

  Gudasheva, Tatiana A ^a,b   Voronina, Tatiana A ^a,b   Ostrovskaya, Rita U ^a,b   Zaitseva, Natalya I ^a,b   Bondarenko, Nina A ^a,b   Briling, Vera K ^a,b   Asmakova, Ludmila S ^a,b   Rozantsev, Grigory G ^a,b   Seredenin, Sergei B ^a,b  

^a INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^b Department of Medicinal Chemistry ^*

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; CLOZAPINE; DIPEPTIDE DERIVATIVE; DOPAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTENSIN DERIVATIVE; REMOXIPRIDE; SULPIRIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CLIMBING; CONTROLLED STUDY; DIASTEREOISOMER; DRUG DESIGN; DRUG EFFECT; DRUG INHIBITION; ESCAPE BEHAVIOR; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C57BL; NEUROTENSIN; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE;

EID: 0032576770     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970217c     Document Type: Article

References (26)

1. Carraway, R.; Leeman, S. E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 1973, 248, 6854-6861.
2. Davis, M. D.; Nemeroff, C. B. Neurotensin, dopamine and schizophrenia. In Receptors and Ligands in Psychiatry; Sen, A. K., Lee, T., Eds., Cambridge University Press: Cambridge, 1988; pp 167-186.
3. Nemeroff, C. B.; Bissette, G.; Prange, A. J., Jr.; Loosen, P. T.; Barlow, T. S.; Lipton, M. A. Neurotensin: Central nervous system effects of a hypothalamic peptide. Brain Res. 1977, 128, 485-496.
4. Luttinger, D.; Nemeroff, C. B.; Prange, A. J., Jr. The effects of neuropeptides on discrete-trial conditioned avoidance responding Brain Res. 1982, 237, 183-2.
5. Nemeroff, C. B.; Luttinger, D.; Hernandez, D. E.; Mailman, R. B.; Mason, G. A.; Davis, S. D.; Widerlov, E.; Frye, G. D.; Kilts, C. A.; Beaumont, K.; Breese, G. R.; Prange, A. J., Jr. Interactions of neurotensin with brain dopamine systems: Biochemical and behavioral studies. J. Pharmacol. Exp. Ther. 1983, 225, 337-345.
6. Luttinger, D.; Nemeroff, C. B.; King R. A.; Ervin, G. N.; Prange, A. J., Jr. The effect of injection of neurotensin into the nucleus accumbens on behaviors mediated by the mesolimbic dopamine system in the rat. In The neurobiology of the Nucleus Accumbens; Chronister, R. B., DeFrance, J. F., Eds.; Haer Institute for Electrophysiological Research: Bar Harbor, Maine, 1981; pp 322-332.
7. Garver, D. L.; Bissette, G.; Yao, J. K.; Nemeroff, C. B. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am. J. Psychiatry 1991, 148, 484-488.
8. Gudasheva, T. A.; Ostrovskaya, R. U.; Trofimov, S. S.; Kosoy, M. Ju.; lenkina, F. V.; Burov, Ju. V.; Skoldinov, A. P. Peptide analogs of piracetam as ligands for hypothetical nootropic receptors. Khim.-Farm. Zh. (Russia) 1985, 19, 1322-1329.
9. Gudasheva, T. A.; Ostrovskaya, R. U.; Trofimov, S. S.; Maximova, F. V.; Kosoy, M. Ju.; Molodavkin, G. M.; Skoldinov, A. P. A possible structure-functional connection between piracetam and vasopressin. Khim.-Farm. Zh. (Russia) 1988, 22, 271-275.
10. Gudasheva, T. A.; Ostrovskaya, R. U. The design of dipeptidal cognitive enhancers based on the structure of non-peptidal nootropic drug piracetam. Can. J. Phys. Pharm. 1994, 72 (Suppl. 1), 213.
11. Edvards, J. G.; Alexander, J. R.; Alexander, M. S.; Gordon, A.; Zuchti, T. Controlled trial of sulpiride in chronic schizophrenic patients. Br. J. Psychiatry 1980, 137, 522.
12. von Euler, G.; Fuxe, K. Neurotensin reduces the affinity of D-2 dopamine receptors in rat striatal membranes. Acta Physiol. Scand. 1987, 131, 625-626.
13. Pozdnev, V. F. The synthesis of tert-butyloxycarbonyl derivatives of some trifunctional amino acids using di-tert-butylpyrocarbonate. Bioorg. Khim. (Russia) 1977, 3, 1605-1610.
14. Anderson, G. V.; Zimmerman, J. E.; Callahan, F. M. Reinvestigation of the mixed carbonic anhydride method of peptide synthesis. J. Am. Chem. Soc, 1967, 89, 5012-5017.
15. Costall, B.; Naylor, R. J.; Nohria, V. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur. J. Pharmacol. 1978, 50, 39-50.
16. Bondarenko, N. A. The selective influence of neuroleptics on dopamine dependent rats behavioral disturbances in the extrapolated escape test. Bull. Exp. Biol. Med, (Russia) 1990, 110, 506-508.
17. Jenner, P.; Marsden, C. D. The mechanism of action of substituted benzamides drugs. In Sulpiride and other Benzamides; Spano, P. F., Trabussihi, M., Corcini, G. U., Gessa, G. L., Eds.; Raven Press: New York, 1979; pp 119-147.
18. Garsia-Lopes, M. T.; Dominiguez, M. J.; Gonzales-Muniz, R.; Herranz, R.; Johansen, N. L.; Madsen, K.; Suzdak, P.; Thogersen, H. Novel 3-oxoindolizidine containing neurotensin (8-13) analogues. In Program and Abstracts: The Thirteenth American Peptide Symposium, Edmonton, Canada, 1993; p 212.
19. Maduskie, T. P., Jr.; Bleicher, L. S.; Cacciola, J.; Cheatham, W.; Fevig, J. M.; Johnson, A. L.; McComb, S. A.; Nugiel, D. A.; Schmidt, W. K.; Spellmeyer, D. A.; Voss, M. E.; Wagner, R. M. The design and synthesis of a peptidomimetic for neurotensin. J. Cell. Biochem. 1993, 57 (Suppl. 17C), 232.
20. Johansen, N. L.; Thogersen, H.; Madsen, K.; Suzdak, P.; Hansen, K. T.; Weis, J. U.; Garsia-Lopez, M. T.; Gome z-Monterrey, L; Gonzalez-Muniz, R.; Herranz, R. Receptor specific neurotensin peptide mimics. In Program and Abstracts: The Thirteenth American Peptide Symposium, Edmonton, Canada, 1993; p 216.
21. Henry, J. A.; Horwell, D. C.; Meecham, K. G.; Rees, D. C. A structure-affinity study of the amino acid side-chains in neurotensin: N and C terminal deletions and Ala-scan. Bioorg. Med. Chem. Lett 1993, 37, 949-952.
22. Gudasheva, T. A.; Voronina, T. A.; Ostrovskaya, R. U.; Rozantsev, G. G.; Vasilevich, N. T.; Trofimov, S. S.; Kravchenko, E. V.; Skoldinov, A. P.; Seredenin, S. B. Synthesis and antiamnesic activity of a series of N-acylprolyl-containing dipeptides. Eur. J. Med. Chem. 1996, 31, 151-157.
23. Florvall, L.; Ögren, S.-O. Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities. J. Med. Chem. 1982, 25, 1280-1286.
24. Howard, H. R.; Lowe, J. A. III; Seeger, T. F.; Seymour, P. A.; Zorn, S. H.; Maloney, P. R.; Ewing, F. E.; Newman, M. E.; Schmidt, A. W.; Furman, J. S.; Robinson, G. L.; Jackson, E.; Johnson, C.; Morrone, J. 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J. Med. Chem. 1996, 39, 143-148.
25. Henning, R.; Lattrell, R.; Gerhards, H. J.; Leven, M. Synthesis and neuroleptic activity of a series of 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl] benziamidazolone derivatives. J. Med. Chem. 1987, 30, 814-819.
26. 3H] Spiperone binding of 3,5-disubstituted N-[1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamides. J. Med. Chem. 1986, 59, 61-69.